Ohguchi, Hiroto

Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma

Mimura, N., Fulciniti, M., Gorgun, G., Tai, Y.-T., Cirstea, D., Santo, L., Hu, Y., Fabre, C., Minami, J., Ohguchi, H., et al. (2012) · Blood

Endoplasmic Reticulum Stress and DiseaseMultiple Myeloma Research and Treatments

Cited by 432

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma

Görgün, G., Samur, M. K., Cowens, K. B., Paula, S., Bianchi, G., Anderson, J. E., White, R. E., Singh, A., Ohguchi, H., Suzuki, R., et al. (2015) · Clinical Cancer Research

Multiple Myeloma Research and TreatmentsCancer Immunotherapy and Biomarkers

Cited by 309

Inflammation-driven senescence-associated secretory phenotype in cancer-associated fibroblasts enhances peritoneal dissemination

Yasuda, T., Koiwa, M., Yonemura, A., Miyake, K., Kariya, R., Kubota, S., Yokomizo-Nakano, T., Yasuda-Yoshihara, N., Uchihara, T., Itoyama, R., et al. (2021) · Cell Reports

Telomeres, Telomerase, and SenescenceTGF-β signaling in diseases

Cited by 165

Histone deacetylase 3 as a novel therapeutic target in multiple myeloma

Minami, J., Suzuki, R., Mazitschek, R., Gorgun, G., Ghosh, B., Cirstea, D., Hu, Y., Mimura, N., Ohguchi, H., Cottini, F., et al. (2014) · Leukemia

Histone Deacetylase Inhibitors ResearchMultiple Myeloma Research and Treatments

Cited by 159

The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications

Ogiya, D., Liu, J., Ohguchi, H., Kurata, K., Samur, M. K., Tai, Y.-T., Adamia, S., Ando, K., Hideshima, T., & Anderson, K. C. (2020) · Blood

Multiple Myeloma Research and TreatmentsCytokine Signaling Pathways and Interactions

Cited by 92

HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications

Harada, T., Ohguchi, H., Grondin, Y., Kikuchi, S., Sagawa, M., Tai, Y.-T., Mazitschek, R., Hideshima, T., & Anderson, K. C. (2017) · Leukemia

Histone Deacetylase Inhibitors ResearchMultiple Myeloma Research and Treatments

Cited by 89

Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma

Fabre, C., Mimura, N., Bobb, K., Kong, S.-Y., Gorgun, G., Cirstea, D., Hu, Y., Minami, J., Ohguchi, H., Zhang, J., et al. (2012) · Clinical Cancer Research

Multiple Myeloma Research and TreatmentsNF-κB Signaling Pathways

Cited by 82